|Bid||7.00 x 1400|
|Ask||6.90 x 1400|
|Day's Range||6.58 - 7.35|
|52 Week Range||6.53 - 19.74|
|Beta (3Y Monthly)||2.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 9, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.30|
SAN DIEGO , Aug. 28, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic ...
Viking Therapeutics, Inc. (VKTX) is currently preparing for the initiation of a Phase 2b clinical trial of VK2809, the company’s thyroid beta receptor (TRβ) agonist, for the treatment of nonalcoholic steatohepatitis (NASH). The company has submitted a pre-IND briefing package to the FDA and is currently awaiting written feedback.
Conference call scheduled for 4:30 p.m. ET today - Preparation for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Underway; Expect to Commence Enrollment in 2H19 - Continued Progress with VK0214 for ...
Conference Call Scheduled for Thursday, August 1 at 4:30 p.m. Eastern Time SAN DIEGO , July 25, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical ...
Is Viking Therapeutics, Inc. (NASDAQ:VKTX) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
Viking Therapeutics (VKTX) stock closed at $7.98 on June 12, 2.70% higher than its previous close, 14.49% above its 52-week low of $6.97, and 66.75% below its 52-week high of $24.
This year, CymaBay Therapeutics (CBAY) has fallen 21.60% and Viking Therapeutics (VKTX) has risen 4.31%. While both clinical-stage companies focus on advancing their nonalcoholic steatohepatitis research and development programs, Viking seems to be ahead, considering its successful Phase 2 trials.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
We can judge whether Viking Therapeutics, Inc. (NASDAQ:VKTX) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best […]
Viking Therapeutics, Inc. (VKTX) is currently preparing for the initiation of a Phase 2b clinical trial of VK2809, the company’s thyroid beta receptor (TRβ) agonist, for the treatment of nonalcoholic steatohepatitis (NASH). While details of the trial have yet to finalized, we do anticipate the trial including biopsy-confirmed NASH patients with F2 and F3 fibrosis (although there are likely to be a small number with F1 fibrosis). Regarding the upcoming trial, based on the length for competitors Phase 2b trials we estimate that if started in the second half of 2019 topline data would probably be available in the first half of 2021, although 4Q20 isn’t out of the question.
Conference call scheduled for 4:30 p.m. ET today - New Data from Phase 2 Study of VK2809 Presented at EASL 2019; Results Demonstrate Robust Efficacy at Doses as Low as 5 mg Daily - Phase 2b Study of VK2809 ...